Biogen and Eisai's Alzheimer's candidate wins priority review in China
China’s NMPA joins other domestic drug authorities in expediting review of lecanemab in the Alzheimer’s disease indication.
by ulrich quistgaard, translated by daniel pedersen
Japanese pharmaceutical company Eisai and US-based biotech company Biogen have just gained access to an approval shortcut in China for Alzheimer’s treatment candidate lecanemab.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Alzheimer's drug wins priority review in Japan
For subscribers
.jpg&w=384&q=75)
